BMRA - Biomerica, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
2.9450
-0.1050 (-3.44%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close3.0500
Open3.0200
Bid2.0100 x 1000
Ask3.0000 x 1000
Day's Range2.9000 - 3.0700
52 Week Range2.6900 - 9.3200
Volume12,341
Avg. Volume9,150
Market Cap26.369M
Beta (3Y Monthly)-0.23
PE Ratio (TTM)N/A
EPS (TTM)-0.1710
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est7.50
Trade prices are not sourced from all markets
  • GlobeNewswire2 days ago

    Biomerica Reports 1st Quarter Fiscal 2019 Financials

    Biomerica, Inc. (BMRA) today reported net sales of $1,272,870 for the three months ending August 31, 2018, compared to $1,444,483 for the same period in the previous year. The Biomerica InFoods® IBS product identifies specific foods that when removed from the patient’s diet can alleviate the patient’s IBS symptoms.

  • Is Biomerica Inc (NASDAQ:BMRA) A Financially Sound Company?
    Simply Wall St.21 days ago

    Is Biomerica Inc (NASDAQ:BMRA) A Financially Sound Company?

    Zero-debt allows substantial financial flexibility, especially for small-cap companies like Biomerica Inc (NASDAQ:BMRA), as the company does not have to adhere to strict debt covenants. However, it also faces higher Read More...

  • Zacks Small Cap Researchlast month

    BMRA: Legacy Biz Slows in Q4. Operational Highlights Include InFoods Enrolling, Ex-Walgreens CMO Joins SAB (and we’re intrigued)

    Biomerica (BMRA) reported financial results for their fiscal 2018 fourth quarter ending May 31, 2018. While our model had revenue inching up 6% for the full-year reflecting an expectation that rebounding sales in Asia would more than offset ongoing softness in both Europe and the U.S., that was far from the case. Instead, the nearly across-the-board (Latin America was the sole bright spot) weakness in Q4, which most notably included a 42% yoy contraction in Asia, resulted in annual sales falling almost 4%.

  • GlobeNewswire2 months ago

    Biomerica Announces Fiscal Year End 2018 Financial Results

    Biomerica, Inc. (BMRA), a global provider of advanced medical products, today reported net sales for the fiscal year 2018 were $5,564,185 versus net sales of $5,791,670 in fiscal 2017.    Net loss was $1,465,828 for fiscal 2018 compared to net loss of $908,561 for fiscal 2017.  Net cash used in operating activities (including research and development) was $1,174,217 for fiscal 2018 compared to $722,858 in fiscal 2017.  Research and Development spending was $1,398,368 for fiscal year 2018 compared to $1,130,635 the previous year, an increase of $267,733, or 23.7%.   The company ended the year with $1,204,903 in cash and cash equivalents, working capital of $3,587,221. “We have achieved significant milestones this year which include the start of the InFoods® diagnostic guided IBS therapy clinical study conducted at Beth Israel Deaconess Medical Center Inc., a Harvard Medical School Teaching Hospital, and at the University of Michigan.

  • GlobeNewswire3 months ago

    Biomerica Receives Notice of Allowance for Irritable Bowel Syndrome (IBS) Test Panel and Methods in Korea

    Biomerica, Inc. (BMRA) announced today that the Korean Intellectual Property Office (KIPO) has issued a Notice of Allowance for a patent application covering Biomerica’s compositions, devices and methods of IBS sensitivity testing. The patent application specifically applies to Biomerica’s InFoods® IBS product, which is currently in a clinical study in the U.S.  This patent would be the first for the InFoods® patent portfolio, providing patent protection for InFoods® IBS in Korea until 2035.

  • When Can We Expect A Profit From Biomerica Inc (NASDAQ:BMRA)?
    Simply Wall St.5 months ago

    When Can We Expect A Profit From Biomerica Inc (NASDAQ:BMRA)?

    Biomerica Inc’s (NASDAQ:BMRA): Biomerica, Inc., together with its subsidiaries, develops, manufactures, and markets medical diagnostic products for the early detection and monitoring of chronic diseases and medical conditions worldwide. WithRead More...

  • Should You Be Concerned About Biomerica Inc’s (NASDAQ:BMRA) Shareholders?
    Simply Wall St.5 months ago

    Should You Be Concerned About Biomerica Inc’s (NASDAQ:BMRA) Shareholders?

    Today, I will be analyzing Biomerica Inc’s (NASDAQ:BMRA) recent ownership structure, an important but not-so-popular subject among individual investors. Ownership structure of a company has been found to affect shareRead More...

  • Zacks Small Cap Research6 months ago

    BMRA: Q3 2018 Results: Asia Remains Strong While U.S., Europe Slip. Encouraged By Robustness of InFoods Study Design

    Biomerica (BMRA) reported financial results for their fiscal 2018 third quarter ending February 28, 2018. Revenue, down 8% yoy and 15% qoq, was softer than we were expecting with both Europe and U.S. sales contributing to the miss. • Fiscal Q3 has historically been a relatively strong quarter for BMRA’s U.S. business – and while that proved to be true as compared to the first two quarters of 2018, on a prior years’ basis, domestic sales were relatively very weak – in fact, the lowest Q3 U.S. number since at least 2009.

  • Does Biomerica Inc’s (NASDAQ:BMRA) Past Performance Indicate A Stronger Future?
    Simply Wall St.6 months ago

    Does Biomerica Inc’s (NASDAQ:BMRA) Past Performance Indicate A Stronger Future?

    For long-term investors, assessing earnings trend over time and against industry benchmarks is more beneficial than examining a single earnings announcement at a point in time. Investors may find myRead More...

  • Biomerica Inc (NASDAQ:BMRA): Is Breakeven Near?
    Simply Wall St.8 months ago

    Biomerica Inc (NASDAQ:BMRA): Is Breakeven Near?

    Biomerica Inc’s (NASDAQ:BMRA): Biomerica, Inc., together with its subsidiaries, develops, manufactures, and markets medical diagnostic products for the early detection and monitoring of chronic diseases and medical conditions worldwide. TheRead More...

  • Zacks Small Cap Research9 months ago

    BMRA: Moving Price Target to $7/Share With Inclusion of InFoods

    Q2 2018 Results: Revenue, particularly in Asia, was very strong. Biomerica (BMRA) reported financial results for their fiscal 2018 second quarter ending November 31, 2017.  And just prior to releasing Q2 results, they made several potentially very substantive announcements related to operational progress of both their legacy business as well as to InFoods – the latter which prompted significant updates to our long-term revenue forecasts as well as to our price target.

  • Biomerica Inc (NASDAQ:BMRA): Poised For Long-Term Success?
    Simply Wall St.9 months ago

    Biomerica Inc (NASDAQ:BMRA): Poised For Long-Term Success?

    Biomerica Inc’s (NASDAQ:BMRA) most recent earnings update in August 2017 revealed company earnings became less negative compared to the previous year’s level as a result of recent tailwinds Investors mayRead More...

  • Is Biomerica Inc (NASDAQ:BMRA) Thriving Or Barely Surviving In The Healthcare Sector?
    Simply Wall St.9 months ago

    Is Biomerica Inc (NASDAQ:BMRA) Thriving Or Barely Surviving In The Healthcare Sector?

    Biomerica Inc (NASDAQ:BMRA), a USD$31.90M small-cap, is a healthcare company operating in an industry, which faces key trends such as rising demand fuelled by an aging population and the growingRead More...

  • Does Biomerica Inc’s (NASDAQ:BMRA) Earnings Growth Make It An Outperformer?
    Simply Wall St.10 months ago

    Does Biomerica Inc’s (NASDAQ:BMRA) Earnings Growth Make It An Outperformer?

    Measuring Biomerica Inc’s (NASDAQ:BMRA) track record of past performance is a valuable exercise for investors. It allows us to understand whether or not the company has met or exceed expectations,Read More...

  • What You Must Know About Biomerica Inc’s (BMRA) Financial Health
    Simply Wall St.10 months ago

    What You Must Know About Biomerica Inc’s (BMRA) Financial Health

    The direct benefit for Biomerica Inc (NASDAQ:BMRA), which sports a zero-debt capital structure, to include debt in its capital structure is the reduced cost of capital. However, the trade-off isRead More...

  • ACCESSWIRE11 months ago

    Biomerica Announces Enrollment of First Patient for H. Pylori Clinical Studies at the University of Southern California

    IRVINE, CA / ACCESSWIRE / November 20, 2017 / Biomerica Inc. (NASDAQ: BMRA ) today announced the enrollment of its first patient at the University of Southern California for the Company's Helicobacter ...

  • Who Are The Major Shareholders In Biomerica Inc (BMRA)?
    Simply Wall St.11 months ago

    Who Are The Major Shareholders In Biomerica Inc (BMRA)?

    In this analysis, my focus will be on developing a perspective on Biomerica Inc’s (NASDAQ:BMRA) latest ownership structure, a less discussed, but important factor. Ownership structure of a company hasRead More...